- Full text PDF available (0)
- This year (0)
- Last 5 years (0)
- Last 10 years (0)
Journals and Conferences
A procedure has been developed to prepare the anthelminthic Rilanide as a fine-dispersed formulation. The therapeutical dose of the agent in fascioliasis and intestinal nematodiasis is 60 mg/kg (for… (More)
AIM To study changes in the condition of lymphocyte membranes of patients with acute viral hepatitis B (AVHB) in narcotic addicts. MATERIALS AND METHODS 136 patients with AVHB have been examined… (More)
A procedure has been developed to manufacture the anthelminthic Triclonate. The agent was tested for the treatment of sheep's natural monieziasis infection and it was found to have a high activity.
The study was undertaken to examine the fasciolacidal activity of the agents G-1411, G-1423, and G-1439. Tested, G-1439 was chosen for detailed investigations as a non-toxic fasciolacide.
A procedure was developed for the synthesis of the anthelminthic G-1460. The therapeutical doses (20 and 25 mg/kg) of the agent were defined for the treatment of monieziasis and gastrointestinal… (More)
The authors describe the technology of preparing a new anthelmintic agent triclazan, N-(3,4-dichlorophenyl)-2-[(benzo-2,1,3-thiadiazole-4-sulfonyl)amino]-5- chlorobenzamide, finely dispersed (the… (More)
A manufacturing procedure has been developed to prepare the anthelmintic bromoxane as a finely divided dosage form. The maximum toxic dose of the drug was 1 g per kg mice body weight. Its therapeutic… (More)